Lyndon Gommersall

Erratum: Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial

Richard T. Bryan, Wenyu Liu, Sarah Pirrie, Jean Gallagher et autres

Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial

Richard T. Bryan, Wenyu Liu, Sarah Pirrie, Jean Gallagher et autres

PURPOSE Transurethral resection of bladder tumor (TURBT) is the initial staging procedure for new bladder cancers (BCs). For muscle-invasive bladder cancers (MIBCs), TURBT may delay definitive treatment. We investigated whether definitive treatment can be expedited for MIBC using flexible cystoscopic biopsy and …

gb (code pays fourni par la source)

719 2WW Prostate Cancer Referrals - Are We Over Investigating Patients with Normal PSA Results?

Manoj Ravindraanandan, K Willard, R Cotton, S Dawson et autres

Abstract Aim Nationally, men are referred by GPs to urologists for suspected prostate cancer using a cancer pathway proforma for an appointment within two weeks. Criteria include a PSA level above the age-specific range, or an abnormal DRE regardless of PSA result. …

gb (code pays fourni par la source)

Should National Institute for Clinical Excellence (NICE) Guidelines Remove Urine Cytology as a Suggested Adjunct in Suspected Bladder Cancer (haematuria) Investigations?

Madeline Moore, Andrew Robinson, Mark Kitchen, Lyndon Gommersall

Background Despite National Institute for Clinical Excellence (NICE) guidelines suggesting the use of urine cytology (UC) for the diagnosis of bladder cancer, its use is variable. Reasons for this include sub-optimal sensitivity, financial cost, availability of alternative tests, and uncertainty over interpretation …

gb (code pays fourni par la source)

1014 Assessment of Prostate Gland Volume Estimations Using MRI And TRUS Compared to Radical Prostatectomy Specimens

Sachin Yallappa, I A Aneke, M. Amjad, Alexandra Clark et autres

Abstract Introduction The prostate volume is an essential criterion to calculate prostate specific antigen density (PSAD). When selecting patients for active surveillance (AS), in newly diagnosed low risk prostate cancer group or continuing AS in previously diagnosed cancer prostate, PSAD plays a …

gb (code pays fourni par la source)

Bladder Cancer

Vineet Agrawal, Lyndon Gommersall, David Mak

Regarding bladder cancer, the following statements are true EXCEPT? The estimated male:female ratio is 2:1. At the initial diagnosis of bladder cancer, 75% of cases are diagnosed as non-muscle-invasive bladder cancer and approximately 25% as muscle-invasive disease. Approximately one-third of patients diagnosed …

HumanMethylation450K Array–Identified Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of High-risk Non-muscle Invasive Bladder Cancer

Mark Kitchen, Richard T. Bryan, Richard D. Emes, Christopher J. Luscombe et autres

BACKGROUND: High-risk non-muscle invasive bladder cancer (HR-NMIBC) is a clinically unpredictable disease. Despite clinical risk estimation tools, many patients are undertreated with intra-vesical therapies alone, whereas others may be over-treated with early radical surgery. Molecular biomarkers, particularly DNA methylation, have been reported …

gb, nl (code pays fourni par la source)

The BCG shortage – what isn't the fuss about?

Vaibhav Modgil, Sophia Cashman, Lyndon Gommersall

A recent widespread shortage of BCG supplies in the UK has resulted in many patients receiving suboptimal doses of BCG or alternative treatment regimens that may not be as effective. The authors consider the lack of media interest in the issue and …

au, gb (code pays fourni par la source)

Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer

Mark Kitchen, Richard T. Bryan, Richard D. Emes, John R. Glossop et autres

High-grade non-muscle invasive bladder cancer (HG-NMIBC) is a clinically unpredictable disease with greater risks of recurrence and progression relative to their low-intermediate-grade counterparts. The molecular events, including those affecting the epigenome, that characterize this disease entity in the context of tumor development, …

gb, nl, tw (code pays fourni par la source)

936 Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer

Mark Kitchen, Richard T. Bryan, Richard D. Emes, John R. Glossop et autres

Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer

Mark Kitchen, Richard T. Bryan, Richard D. Emes, John R. Glossop et autres

High-grade non-muscle invasive bladder cancer (HG-NMIBC) is a clinically unpredictable disease with greater risks of recurrence and progression relative to their low-intermediate-grade counterparts. The molecular events, including those affecting the epigenome, that characterize this disease entity in the context of tumor development, …

Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer

Mark Kitchen, Richard T. Bryan, Kim E. Haworth, Richard D. Emes et autres

INTRODUCTION: Inappropriate DNA methylation is frequently associated with human tumour development, and in specific cases, is associated with clinical outcomes. Previous reports of DNA methylation in low/intermediate grade non-muscle invasive bladder cancer (NMIBC) have suggested that specific patterns of DNA methylation may …

gb, nl (code pays fourni par la source)